FLG rs61814899: What Your Genotype Means
The genetic variant rs61814899 is a loss-of-function stop-gain mutation within the filaggrin (FLG) gene, designated at the cDNA level as c.1501A>T (p.Lys501Ter). This variation impairs the production of the filaggrin protein, which is essential for maintaining epidermal integrity and moisture retention. As a result, carrying this variant is associated with reduced skin barrier function, heightened susceptibility to atopic eczema (dermatitis), and an increased likelihood of allergen sensitization.
What each genotype means
| Genotype | What the research suggests | Reading |
|---|---|---|
| AA | The individual carries two copies of the standard reference allele. This genotype is not associated with filaggrin-related barrier protein deficiency or increased baseline genetic risk for atopic eczema at this specific locus. | Favorable |
| AT | The individual is heterozygous for the stop-gain variant, carrying one normal allele and one truncated allele. This status is associated with reduced filaggrin levels, higher transepidermal water loss, and an increased statistical predisposition to atopic dermatitis and allergic sensitization. | Higher attention |
| TT | The individual carries two copies of the stop-gain variant. Biallelic loss of functional filaggrin typically results in a pronounced loss of skin barrier function, strongly predisposing the individual to severe atopic eczema or ichthyosis vulgaris. | Higher attention |
Understanding rs61814899 and the FLG Gene
The single nucleotide polymorphism (SNP) rs61814899 is located on chromosome 1 within the filaggrin (FLG) gene. At this position, an adenine base is replaced by a thymine base (c.1501A>T). In protein coding, this transition substitutes a lysine codon with a premature termination codon (p.Lys501Ter), also historically annotated in scientific literature as a stop-gain mutation truncating the filaggrin precursor. The FLG gene provides instructions for building profilaggrin, a large polyprotein that undergoes proteolytic processing into individual filaggrin peptides. Filaggrin is indispensable for assembling keratin intermediate filaments into tight bundles in the outermost epidermal layer, the stratum corneum. These bundles ensure structural strength and cellular cohesion, forming an impermeable defense against moisture loss, chemical irritants, and external environmental pathogenetic factors.
Biological Consequences of Barrier Disruption
When a stop-gain variant such as rs61814899 truncates profilaggrin translation, keratinocytes fail to accumulate sufficient functional filaggrin monomers. Filaggrin degradation normally produces natural moisturizing factor (NMF), a pool of amino acids and organic acids essential for skin hydration, acidic barrier maintenance, and antimicrobial defense. A deficiency in filaggrin leads to an elevated transepidermal water loss (TEWL) and a structurally compromised skin barrier. This structural defect allows environmental antigens, microscopic pathogens, and dietary allergens to penetrate the stratum corneum more easily. Once past the weakened stratum corneum, foreign antigens encounter antigen-presenting cells in the dermis, instigating a localized T-helper type 2 (Th2) immune cascade that triggers chronic inflammation, dryness, pruritus, and epicutaneous immune sensitization.
Clinical Associations: Eczema and Allergic Sensitization
Extensive dermatological studies highlight loss-of-function FLG mutations as primary genetic predisposing factors for atopic eczema and ichthyosis vulgaris. Carrying a heterozygous loss-of-function FLG allele confers a significantly higher relative risk of developing childhood-onset atopic dermatitis. Furthermore, because of compromised epicutaneous integrity, individuals harboring variants like rs61814899 frequently present with the 'atopic march'—a clinical progression from infantile eczema to subsequent allergic rhinitis, asthma, and IgE-mediated food allergies, including peanut reactivity. Although the statistical association is robust, penetrance is incomplete. Carrying the risk allele increases susceptibility but does not guarantee the onset of eczema, as clinical presentation depends on diverse environmental influences, climate, humidity, and co-inherited immune-modulating loci.
Population Distribution and Ancestry Differences
The prevalence of FLG loss-of-function variants varies substantially across global populations. Based on public sequencing databases including the Genome Aggregation Database (gnomAD), the rs61814899 variant exhibits a minor allele frequency (MAF) of approximately 0.015 to 0.02 (1.5% to 2%) in populations of European descent. In contrast, it is found at extremely low frequencies or is entirely absent in most East Asian, African, and Indigenous American ancestry groups. This disparity reflects the historical founder effects and population-specific mutational spectra observed throughout the FLG locus, where distinct loss-of-function alleles arose and persisted predominantly in specific geographic regions rather than ubiquitously across global ancestries.
Translating Genetic Results into Action
A genetic result indicating the presence of rs61814899 serves as an informative indicator of skin barrier biology, not a clinical diagnosis. Genotyping cannot predict disease severity or ensure whether skin conditions will manifest. Individuals carrying this variant can prioritize general barrier-protective skin regimens, such as regular application of ceramide-rich moisturizers, avoiding harsh detergents, and minimizing exposure to verified contact allergens. Those experiencing persistent skin inflammation, severe dryness, or symptoms of atopic allergies should consult a dermatologist or allergist for targeted diagnostic evaluation. Genetic data should be integrated with personal medical history rather than used to self-treat or implement restrictive dietary eliminations without professional oversight.
How common is this variant?
The rs61814899 minor allele (T) has a frequency of approximately 1.5% to 2% (MAF ~0.015-0.02) among individuals of European ancestry according to gnomAD, while remaining rare or unobserved in non-European ancestral groups.
Frequently asked questions
What does a positive result for FLG rs61814899 mean?
Carrying this variant means that one or both copies of your FLG gene have a premature stop codon, leading to lower levels of functional filaggrin protein. This creates a more permeable skin barrier, statistically elevating your likelihood of developing dry skin, atopic dermatitis, and environmental or food allergen sensitivities.
Does carrying rs61814899 guarantee that I will get eczema?
No, carrying the variant does not guarantee that you will develop eczema or allergies. The variant exhibits incomplete penetrance, meaning that environmental factors, humidity levels, microbiome balance, and other genetic factors also influence whether skin inflammation manifests.
Can this genetic variant cause severe food allergies?
While the FLG gene does not directly control food digestion, a compromised skin barrier permits food proteins to enter through broken or inflamed skin. This epicutaneous exposure can stimulate an allergic immune sensitization, which researchers have linked to an increased risk of food allergies, such as peanut allergy.
How is rs61814899 related to ichthyosis vulgaris?
Ichthyosis vulgaris is an inherited skin condition characterized by dry, scaly skin. Biallelic inheritance (two copies) of FLG loss-of-function variants is the primary genetic cause of moderate to severe ichthyosis vulgaris, while carrying a single copy can lead to mild, semi-dominant manifestations.
Sources & further reading
Educational information only, last refreshed 9/10/2026. Not medical advice — these associations describe population statistics, not individual predictions.
Curious what your genotype is for rs61814899?
Upload a raw DNA file from 23andMe, AncestryDNA, MyHeritage, or FamilyTreeDNA and see this variant — plus thousands more — interpreted in your full report.
Get my report — $29